Alkermes (NASDAQ: ALKS) is a global biopharmaceutical company that develops medicines for central nervous system diseases. The company has a current market capitalization of approximately $5.56 billion. Market capitalization represents the total dollar value of a company's outstanding shares and is a common measure of a company's size.
On May 1, 2026, an executive at Alkermes, Hopkinson Craig C., sold 9,000 Ordinary Shares. The shares were sold at a price of $33.40 each. Following this insider transaction, the executive's remaining holding in the company consists of 81,389 shares. This type of sale by a high-level employee is known as an insider transaction.
The timing of this executive stock sale is notable as it occurs just before a significant company event. As reported by Business Wire, Alkermes will host a conference call on May 5, 2026, to discuss its first-quarter financial results. This places the executive's stock sale only a few days before the public earnings announcement.
Analysts are watching the upcoming report closely. As highlighted by Zacks, Alkermes is expected to show a year-over-year decline in earnings, with a projected quarterly loss of $0.57 per share. These analyst expectations can create uncertainty around the stock's performance following the release of the actual financial results.
Currently, Alkermes trades at $33.38 per share, which is very close to the price at which the executive sold his shares. The stock's price has moved between a day low of $33.12 and a day high of $33.90, with a 52-week range of $25.17 to $36.48.
